NASDAQ:INBX Inhibrx (INBX) Stock Price, News & Analysis → “The Biggest Bubble of All Time” – Here’s What to Do. (From Chaikin Analytics) (Ad) Free INBX Stock Alerts $34.10 -0.28 (-0.81%) (As of 11:58 AM ET) Add Compare Share Share Today's Range$34.02▼$34.1950-Day Range$34.10▼$39.5652-Week Range$14.31▼$39.79Volume34,818 shsAverage Volume671,395 shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$27.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Inhibrx alerts: Email Address Inhibrx MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside21.5% Downside$27.00 Price TargetShort InterestBearish6.04% of Float Sold ShortDividend StrengthN/ASustainability-1.21Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.11 out of 5 starsMedical Sector529th out of 907 stocksBiological Products, Except Diagnostic Industry84th out of 153 stocks 1.0 Analyst's Opinion Consensus RatingInhibrx has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageInhibrx has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.04% of the float of Inhibrx has been sold short.Short Interest Ratio / Days to CoverInhibrx has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Inhibrx has recently increased by 34.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInhibrx does not currently pay a dividend.Dividend GrowthInhibrx does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInhibrx has received a 71.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for deficiency diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Inhibrx is -1.21. Previous Next 2.1 News and Social Media Coverage News SentimentInhibrx has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inhibrx insiders have not sold or bought any company stock.Percentage Held by Insiders22.20% of the stock of Inhibrx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibrx is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibrx is -6.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibrx has a P/B Ratio of 37.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Chaikin Analytics“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.Just click here. About Inhibrx Stock (NASDAQ:INBX)Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Read More INBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INBX Stock News HeadlinesApril 16, 2024 | msn.comAs more rare disease therapies launch, their prices are risingMarch 16, 2024 | finance.yahoo.comINBX Apr 2024 50.000 putApril 25, 2024 | Chaikin Analytics (Ad)“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.March 16, 2024 | finance.yahoo.comINBX Apr 2024 55.000 callFebruary 29, 2024 | realmoney.thestreet.comInhibrx just downgraded at Jefferies, here's whyFebruary 28, 2024 | finanznachrichten.deInhibrx, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 28, 2024 | prnewswire.comInhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsFebruary 10, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXApril 25, 2024 | Chaikin Analytics (Ad)“The Biggest Bubble of All Time” – Here’s What to Do.Despite AI's incredible run-up in 2023, we're getting some conflicting messages. Analysts at JP Morgan warn that an "AI-driven bubble" could drag the entire stock market down. Folks at Morgan Stanley say AI hysteria is creating conditions like the dot-com collapse. Even AI leaders (the people who benefit the most!) are getting worried.February 10, 2024 | businesswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXJanuary 24, 2024 | msn.comSanofi signs agreement to acquire Inhibrx for $1.7bnJanuary 24, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & MoreJanuary 24, 2024 | seekingalpha.comSanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 AcquisitionJanuary 24, 2024 | finance.yahoo.comInhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?January 24, 2024 | realmoney.thestreet.comInhibrx just downgraded at LifeSci Capital, here's whyJanuary 23, 2024 | msn.comThese Stocks Are Moving the Most Today: United, Logitech, Archer Daniels, Inhibrx, J&J, Netflix, and MoreJanuary 23, 2024 | marketwatch.comSanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- UpdateJanuary 23, 2024 | reuters.comFrance's Sanofi to buy U.S. drugs project INBRX-101 for about $2.2 blnJanuary 23, 2024 | tmcnet.comINBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to ShareholdersDecember 9, 2023 | morningstar.comInhibrx Inc Ordinary Shares INBXDecember 2, 2023 | morningstar.comInhibrx Inc Ordinary SharesNovember 10, 2023 | msn.comInhibrx posts Q3 resultsNovember 10, 2023 | finanznachrichten.deInhibrx, Inc.: Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNovember 9, 2023 | finance.yahoo.comInhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNovember 4, 2023 | msn.comInhibrx reports initial Phase I Ewing sarcoma trial dataNovember 2, 2023 | finance.yahoo.comInhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing SarcomaSeptember 19, 2023 | finance.yahoo.comInhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and CanadaSee More Headlines Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/25/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INBX CUSIPN/A CIK1739614 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees166Year FoundedN/APrice Target and Rating Average Stock Price Target$27.00 High Stock Price Target$27.00 Low Stock Price Target$27.00 Potential Upside/Downside-21.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-241,360,000.00 Net Margins-13,408.95% Pretax Margin-13,318.00% Return on Equity-590.78% Return on Assets-84.13% Debt Debt-to-Equity Ratio4.78 Current Ratio5.24 Quick Ratio5.25 Sales & Book Value Annual Sales$1.80 million Price / Sales905.15 Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book37.37Miscellaneous Outstanding Shares47,390,000Free Float36,871,000Market Cap$1.63 billion OptionableOptionable Beta2.91 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Mark Paul Lappe (Age 56)Founder, Chairman, President & CEO Comp: $1.1MDr. Brendan P. Eckelman Ph.D. (Age 44)Founder & Chief Scientific Officer Comp: $769.25kMs. Kelly Devine Deck B.S. (Age 43)CPA, M.S., Executive VP & CFO Comp: $636.87kMr. Quinn L. DeverauxFounderDr. Ashraf Amanullah (Age 56)Executive VP & Chief Technical Operations Officer Ms. Leah Pollema J.D.VP, Corporate Secretary & General CounselDr. Charbel Helaihel Pharm.D.Vice President of Marketing & Commercial PlanningMr. Jeffrey J. JensenExecutive VP & Chief Clinical Operations OfficerMr. David Matly M.B.A.Executive VP and Chief Commercial & Business Development OfficerDr. Carlos Bais Ph.D.Executive Vice President of Translational SciencesMore ExecutivesKey CompetitorsNeumora TherapeuticsNASDAQ:NMRAADMA BiologicsNASDAQ:ADMASana BiotechnologyNASDAQ:SANARecursion PharmaceuticalsNASDAQ:RXRXFusion PharmaceuticalsNASDAQ:FUSNView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Bought 744 shares on 4/17/2024Ownership: 0.064%Wellington Management Group LLPSold 29,501 shares on 3/5/2024Ownership: 0.307%Readystate Asset Management LPBought 13,839 shares on 2/20/2024Ownership: 0.029%PFM Health Sciences LPBought 249,347 shares on 2/15/2024Ownership: 1.138%Birchview Capital LPSold 22,000 shares on 2/15/2024Ownership: 0.102%View All Insider TransactionsView All Institutional Transactions INBX Stock Analysis - Frequently Asked Questions Should I buy or sell Inhibrx stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INBX, but not buy additional shares or sell existing shares. View INBX analyst ratings or view top-rated stocks. What is Inhibrx's stock price target for 2024? 2 brokers have issued twelve-month price targets for Inhibrx's shares. Their INBX share price targets range from $27.00 to $27.00. On average, they anticipate the company's stock price to reach $27.00 in the next year. This suggests that the stock has a possible downside of 21.5%. View analysts price targets for INBX or view top-rated stocks among Wall Street analysts. How have INBX shares performed in 2024? Inhibrx's stock was trading at $38.00 on January 1st, 2024. Since then, INBX stock has decreased by 9.5% and is now trading at $34.38. View the best growth stocks for 2024 here. Are investors shorting Inhibrx? Inhibrx saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,150,000 shares, an increase of 34.4% from the March 15th total of 1,600,000 shares. Based on an average daily volume of 726,500 shares, the days-to-cover ratio is presently 3.0 days. Currently, 6.0% of the shares of the stock are short sold. View Inhibrx's Short Interest. When is Inhibrx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our INBX earnings forecast. How were Inhibrx's earnings last quarter? Inhibrx, Inc. (NASDAQ:INBX) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by $0.66. The firm had revenue of $1.63 million for the quarter, compared to analysts' expectations of $0.10 million. Inhibrx had a negative net margin of 13,408.95% and a negative trailing twelve-month return on equity of 590.78%. What ETFs hold Inhibrx's stock? ETFs with the largest weight of Inhibrx (NASDAQ:INBX) stock in their portfolio include ProShares Merger ETF (MRGR), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and IQ Merger Arbitrage ETF (MNA).iShares Micro-Cap ETF (IWC). What other stocks do shareholders of Inhibrx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU). When did Inhibrx IPO? Inhibrx (INBX) raised $102 million in an initial public offering (IPO) on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx's major shareholders? Inhibrx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.06%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe. View institutional ownership trends. How do I buy shares of Inhibrx? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INBX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsPrepare for a recession unlike any otherAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
